Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Erythrocytic parameters and thrombin generation assay measurement.
- Who it may be relevant to
- Registry conditions: Sickle Cell Disease, Vaso-occlusive Crisis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease
Overview
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.
Interventions
- Biological Erythrocytic parameters and thrombin generation assay measurement
Erythrocytic parameters and thrombin generation assay measurement
Primary outcome measures
- Hospitalisation for Vaso-occlusive crisis within one years [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Sickle cell disease
Exclusion criteria
- <18 years
- pregnancy
- Patient under protective guardianship or curatorship
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Rouen university Hospital — Rouen
Publications
- Feugray G, Grall M, Gillardin B, Burdeau J, Ozanne N, Dumesnil C, Fauvel C, Billoir P. Hemoglobin and High-Density Lipoprotein as Biomarker of Left Atrial Dilatation in Sickle Cell Disease. EJHaem. 2025 Aug 22;6(4):e70135. doi: 10.1002/jha2.70135. eCollection 2025 Aug. PMID 40862241
Identifiers
NCT: NCT05376046 · 2021/0328/OB